Journal of Pharmaceutical and Biomedical Analysis 2016-05-10

Validation of a simple HPLC-UV method for rifampicin determination in plasma: Application to the study of rifampicin arteriovenous concentration gradient.

Sébastien Goutal, Sylvain Auvity, Tiphaine Legrand, Fanny Hauquier, Salvatore Cisternino, Hélène Chapy, Wadad Saba, Nicolas Tournier

Index: J. Pharm. Biomed. Anal. 123 , 173-8, (2016)

Full Text: HTML

Abstract

In clinical practice, rifampicin exposure is estimated from its concentration in venous blood samples. In this study, we hypothesized that differences in rifampicin concentration may exist between arterial and venous plasma. An HPLC-UV method for determining rifampicin concentration in plasma using rifapentine as an internal standard was validated. The method, which requires a simple protein precipitation procedure as sample preparation, was performed to compare venous and arterial plasma kinetics after a single therapeutic dose of rifampicin (8.6 mg/kg i.v, infused over 30 min) in baboons (n=3). The method was linear from 0.1 to 40 μg mL(-1) and all validation parameters fulfilled the international requirements. In baboons, rifampicin concentration in arterial plasma was higher than in venous plasma. Arterial Cmax was 2.1±0.2 fold higher than venous Cmax. The area under the curve (AUC) from 0 to 120 min was ∼80% higher in arterial plasma, indicating a significant arteriovenous concentration gradient in early rifampicin pharmacokinetics. Arterial and venous plasma concentrations obtained 6h after rifampicin injection were not different. An important arteriovenous equilibration delay for rifampicin pharmacokinetics is reported. Determination in venous plasma concentrations may considerably underestimate rifampicin exposure to organs during the distribution phase.Copyright © 2016 Elsevier B.V. All rights reserved.


Related Compounds

  • Rifapentine
  • Lithium iodoacetat...

Related Articles:

Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.

2014-06-01

[Antimicrob. Agents Chemother. 58(6) , 3168-76, (2014)]

Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.

2015-08-03

[Mol. Pharm. 12 , 2594-603, (2015)]

Bacteriological characterization of a Mycobacterium parascrofulaceum strain isolated from a Chinese pneumonia patient.

2014-08-01

[Int. J. Infect. Dis. 25 , 82-7, (2014)]

Inhibitory Potential of Twenty Five Anti-tuberculosis Drugs on CYP Activities in Human Liver Microsomes.

2015-01-01

[Biol. Pharm. Bull. 38 , 1425-9, (2015)]

Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.

2015-07-01

[Antimicrob. Agents Chemother. 59 , 4012-9, (2015)]

More Articles...